Proshares Trust (ZBIO) EBIAT (2023 - 2025)
Historic EBIAT for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to -$51.5 million.
- Zenas BioPharma's EBIAT fell 3339.9% to -$51.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$189.9 million, marking a year-over-year decrease of 4723.51%. This contributed to the annual value of -$157.0 million for FY2024, which is 32290.7% down from last year.
- Zenas BioPharma's EBIAT amounted to -$51.5 million in Q3 2025, which was down 3339.9% from -$52.2 million recorded in Q2 2025.
- Zenas BioPharma's 5-year EBIAT high stood at $35.6 million for Q3 2023, and its period low was -$52.6 million during Q4 2024.
- In the last 3 years, Zenas BioPharma's EBIAT had a median value of -$38.0 million in 2024 and averaged -$31.5 million.
- As far as peak fluctuations go, Zenas BioPharma's EBIAT plummeted by 20841.95% in 2024, and later tumbled by 2086.33% in 2025.
- Over the past 3 years, Zenas BioPharma's EBIAT (Quarter) stood at -$24.6 million in 2023, then plummeted by 113.93% to -$52.6 million in 2024, then rose by 2.09% to -$51.5 million in 2025.
- Its last three reported values are -$51.5 million in Q3 2025, -$52.2 million for Q2 2025, and -$33.6 million during Q1 2025.